RIA-01 · Work Package 1.4 · Competitor Pipeline Map
v0.1 · 2026-05-11
Reprogramming Biotech Competitive Landscape
Publicly-disclosed pipelines, focus areas, and modality choices for the major partial-reprogramming biotechs — with a target-overlap matrix and the white-space they leave behind.
Computational research use only — not clinical, not therapeutic, not wet-lab instruction. All competitor information drawn from public disclosures (company websites, press releases, conference presentations, regulatory filings, journalism). No proprietary information used.
Source discipline: Pipeline details below are based on company public disclosures and reputable trade press coverage as of search date (mid-2026). Private programs and unannounced work are not included. Where information is dated or unverified, this is flagged explicitly per company.
1. Snapshot — 9 disclosed players
| # | Company | Founded / Funding | Primary modality | Stated focus | Stage | Competitive tier |
| 1 | Altos Labs | 2021 / reportedly ~$3B | TF biology, multiple modalities | Cellular rejuvenation programming | Discovery / preclinical | Tier 1 (largest) |
| 2 | Retro Biosciences | 2021 / ~$180M (Altman, others) | Multimodal partial reprogramming | Cellular & plasma reprogramming; autophagy | Discovery | Tier 1 |
| 3 | NewLimit | 2021 / Coinbase founders | TF screens (CRISPR-Cas-based) | Cell-type-specific reprogramming | Discovery | Tier 1 |
| 4 | Life Biosciences | 2017 / Sinclair-affiliated | AAV-OSK | Vision (RGC rejuvenation), other tissues | Preclinical → IND-enabling | Tier 2 |
| 5 | Iduna Therapeutics | Life Bio spinout | AAV-OSK | Eye / CNS first indications | Preclinical | Tier 2 |
| 6 | Turn Biotechnologies | 2018 / Sebastiano (Stanford) | mRNA-OSKMLN (transient) | Aging skin, immune cells, joints | Preclinical | Tier 2 |
| 7 | Rejuvenate Bio | 2017 / Church-affiliated | AAV (multiple cargos) | Veterinary first, longevity targets | Preclinical (veterinary commercial) | Tier 2 |
| 8 | Genflow Biosciences | 2020 / publicly listed (LSE) | AAV-SIRT6 (centenarian variant) | SIRT6 gene therapy for aging | IND-stage | Tier 2 |
| 9 | BioAge Labs | 2015 / public 2024 (Nasdaq) | Small molecule (apelin agonist + others) | Geroscience / muscle aging | Phase 2 (clinical) | Tier 3 (adjacent) |
2. Tier 1 deep cards
Altos Labs
Founded 2021 · Hal Barron CEO · Cambridge UK / Bay Area / San Diego campuses · Backers reportedly include Bezos, Yuri Milner
TF biology
Small molecule
AAV (likely)
PUBLIC DISCLOSURE
Altos's institute structure rather than typical biotech: Cambridge (UK) institute led by Wolf Reik; Bay Area led by Manuel Serrano; senior scientists include Juan Carlos Izpisua Belmonte (formerly Salk), Shinya Yamanaka (Nobel laureate, scientific advisor). Programs are not publicly disclosed at the indication or molecule level. The institute model suggests platform / multi-modality, not a focused first-in-human asset.
INFERENCE FROM TEAM COMPOSITION
Reik's group is canonical for chromatin and reprogramming (DNA methylation, X-inactivation, naive pluripotency). Serrano's group is canonical for partial reprogramming in vivo. Belmonte authored the foundational Ocampo 2016 in vivo partial reprogramming paper. The team composition implies strong focus on TF-based reprogramming biology with whatever delivery best fits each tissue — not a small-molecule-first program.
WHITE SPACE THEY LEAVE
No public disclosure of a KAT8/H4K16ac program. No disclosed program on TET-cofactor priming. The Altos approach appears to be predominantly TF-and-delivery; the chemical-priming / epigenetic-tool-compound layer is not a stated focus. This is consistent with the WP1.2 white-space findings.
Retro Biosciences
Founded 2021 · Sam Altman ~$180M backer · San Francisco · Joe Betts-LaCroix, others
TF biology
mRNA
AAV (likely)
PUBLIC DISCLOSURE
Three stated focus areas: cellular reprogramming, plasma-based interventions, and autophagy. Mission is to add ~10 years of healthy human life. Less institute-flavored than Altos; structured as a more conventional biotech with multiple platform "shots."
INFERENCE
The autophagy track suggests small-molecule chemistry is a real lane for Retro (autophagy inducers like spermidine, urolithin A analogs, mTOR-axis tools). But the chemistry is autophagy-centric, not partial-reprogramming-centric. The reprogramming work is TF-based.
WHITE SPACE THEY LEAVE
No public disclosure of an epigenetic-priming small molecule program adjacent to their reprogramming work. The H4K16ac axis is unaddressed. TET cofactor priming is unaddressed.
NewLimit
Founded 2021 · Brian Armstrong (Coinbase), Blake Byers backers · South San Francisco
TF screens
PUBLIC DISCLOSURE
Founded explicitly around large-scale TF and TF-combination screens to find cell-type-specific reprogramming factor cocktails (beyond OSKM). Computational + experimental pairing. Co-founded by Hannu Rajaniemi (also CTO). Hepatocyte and T cell programs publicly mentioned.
INFERENCE
Pure TF-discovery play. Almost certainly not running parallel small-molecule chemical-priming programs. Their differentiation is in the screening infrastructure (CRISPRa libraries, high-content imaging), not in the chemical biology.
WHITE SPACE THEY LEAVE
All chemical-priming axes. NewLimit's TF screens may well rediscover the need for chemical priming when their factor cocktails plateau on efficiency — a future partnership opportunity for an Atlas Bio chemical-priming asset.
3. Tier 2 deep cards
Life Biosciences & Iduna Therapeutics
Life: 2017 · Sinclair-affiliated · Multiple "daughter companies" by mechanism · Iduna: AAV-OSK spinout
AAV-OSK
TF biology
PUBLIC DISCLOSURE
Life Biosciences is structured as a holding/platform company spinning out programs by mechanism. Iduna Therapeutics is the dedicated AAV-OSK delivery program, advancing toward IND-enabling work in eye (vision restoration, building on Lu et al. 2020 Nature) and other tissues. Sinclair as scientific advisor.
INFERENCE
Most direct overlap with Atlas Bio's existing AAV capsid platform. Iduna's delivery choices (AAV9, PHP.eB-class, retinal AAVs) sit in the same space Atlas Bio scores.
This is the most strategically important competitor to map AND a plausible partner.
WHITE SPACE THEY LEAVE
Iduna is AAV-OSK-first; chemical-priming is not in the disclosed plan. A chemical-priming asset that sensitizes tissue for AAV-OSK is precisely the complementary upstream/downstream sale.
Turn Biotechnologies
2018 · Vittorio Sebastiano (Stanford) co-founder · mRNA-based
mRNA-OSKMLN
PUBLIC DISCLOSURE
Builds on Sarkar et al. 2020 (Nat Commun) showing transient mRNA delivery of OSKMLN rejuvenates aged human cells. First indications: aging skin, T cell rejuvenation, cartilage. Avoiding AAV avoids cargo-size, immunogenicity, and re-dosing constraints.
INFERENCE
mRNA-first commits Turn to a different delivery paradigm than Atlas Bio's AAV strength. Not a direct overlap. Worth tracking because if mRNA dosing wins in skin / cartilage, the field broadens.
WHITE SPACE THEY LEAVE
No chemical-priming program. mRNA platform decisions don't displace small-molecule chemistry; they complement it.
Genflow Biosciences
2020 · LSE-listed (GENF.L) · AAV-SIRT6
AAV-SIRT6
PUBLIC DISCLOSURE
Lead asset GF-1002: AAV9-delivered centenarian SIRT6 variant for aging-associated disease. IND-enabling. The centenarian SIRT6 variant has stronger DNA repair activity than wild-type.
INFERENCE — AND THE NAD+/SIRT6/KAT8 NEXUS
Critical: SIRT6 is the primary mammalian H4K16 deacetylase. Genflow's program
increases SIRT6 activity, which lowers H4K16ac — the exact opposite direction of WP2.1's KAT8 activator program. This is the same mechanistic conflict surfaced in WP1.3 (NAD+/SIRT6 antagonism with KAT8/H4K16ac), now embodied in a clinical-stage program.
STRATEGIC IMPLICATION
Atlas Bio's KAT8 program and Genflow's SIRT6 program would be mechanistic competitors in any patient who tried both. The defensible framing: SIRT6 augmentation and KAT8 activation may both extend healthspan via different epigenetic-mark axes (SIRT6 favors H3K9 / DNA-damage-response; KAT8 specifically restores H4K16ac). Worth a dedicated white paper.
4. Target-axis overlap matrix (vs. RIA-01 white-space findings)
Maps each competitor against the chemical / mechanistic axes RIA-01 has flagged as high-opportunity.
| Axis (RIA-01 ranking) |
Altos | Retro | NewLimit | Life/Iduna | Turn | Genflow | BioAge |
White space? |
| KAT8 / H4K16ac activator (WP2.1 headline) |
No | No | No | No | No | Indirect (opposite direction) | No |
YES — total gap |
| TET cofactor priming (Vit C, α-KG) |
No | No | No | No | No | No | No |
YES |
| Tazemetostat / selective EZH2-i upgrade |
No | No | No | No | No | No | No |
YES |
| WDR5 / MLL antagonism |
Maybe (Reik chromatin lab) | No | No | No | No | No | No |
YES |
| AAV-OSK delivery |
Maybe | Maybe | No | YES | No | YES (SIRT6 cargo) | No |
Crowded |
| mRNA-OSK(MLN) delivery |
Maybe | Maybe | No | No | YES (lead) | No | No |
Moderate |
| TF screens / novel factor cocktails |
YES | YES | YES (lead) | Maybe | Maybe | No | No |
Saturated |
| NAD+ / SIRT axis |
No | No | No | No | No | YES (lead) | Adjacent |
Different axis (longevity) |
Yes/No/Maybe is RIA-01's inference from public disclosure only. Private programs may differ.
5. Strategic implications for Atlas Bio
5A. WP1.2's white-space findings hold under competitive scrutiny
- None of the 9 disclosed players has a KAT8/H4K16ac activator program. The WP2.1 finding survives.
- None has a TET-cofactor priming program. The Vitamin C / α-KG opportunity survives.
- None has a Tazemetostat / selective-EZH2-i upgrade-path program. The DZNep-upgrade opportunity survives.
5B. The delivery layer is contested but Atlas Bio has a real advantage
- Life/Iduna and Genflow are the direct AAV competitors. Atlas Bio's capsid intelligence platform (BBB-capable variants scored: PHP.eB 0.71, AAV9 0.65, 4D-R100 0.43) is differentiating in the engineered-capsid lane neither competitor publicly addresses.
- WP3 (delivery pairing) will quantify this advantage.
5C. The Genflow / SIRT6 conflict is the most important strategic question
- If Atlas Bio advances a KAT8-axis program, the SIRT6-augmentation story (Genflow's lead asset) becomes a directly contradictory narrative in patient and investor conversations.
- The defensible framing — SIRT6 and KAT8 address different epigenetic marks (H3K9 / DNA-damage-response vs. H4K16ac specifically) — needs to be in the WP-final white paper.
5D. Partnership candidates by current overlap
- Iduna Therapeutics — most direct delivery overlap. A chemical-priming asset that sensitizes tissue for AAV-OSK is the natural complementary sale.
- NewLimit — TF screens will eventually need chemistry. Plausible licensing target if Atlas Bio's chemical-priming portfolio matures.
- Turn Bio — mRNA delivery is orthogonal but the rejuvenation indication set overlaps; possible co-development on skin / immune cell programs.
6. Limitations of this pass
- Public disclosure is incomplete. Each of the Tier 1 companies (Altos, Retro, NewLimit) almost certainly has private programs not captured here.
- Funding amounts are journalist-reported and may be outdated.
- Pipeline timelines are not included — competitor IND timing is a separate WP1.5 question.
- Academic labs (Sinclair, Belmonte, Serrano, Reik, Wagers, Conboy, Sebastiano) are mostly captured via their affiliated companies but a parallel "academic competitive landscape" pass is recommended.
- This map will go stale within 6–12 months as Tier 1 disclosures emerge. Recommend WP1.4-refresh quarterly.